Daiichi Sankyo posts positive DS-9606 clinical trial results in solid tumours - Yahoo Finance

Daiichi Sankyo reports positive Phase I trial findings for DS-9606, an ADC targeting CLDN6 in advanced solid tumours, showing promising clinical activity and safety.